On systemic antibiotics or with an active bacterial infection at the time of surgery
Patients previously enrolled in this trial
Patients known to be colonized with Methicillin-resistant S. aureus (MRSA)(unethical not to administer glycopeptides), beta-lactam or vancomycin allergy precluding the use of cefazolin or vancomycin, respectively, or to silver precluding the use of Prevena
Participation in other studies that may interfere with this trial

NCT03402945_exc_T1
Drug
systemic antibiotics
NCT03402945_exc_T2
Condition
bacterial infection
NCT03402945_exc_T3
Qualifier
active
NCT03402945_exc_T4
Temporal
at the time of surgery
NCT03402945_exc_T5
Reference_point
the time of surgery
NCT03402945_exc_T6
Procedure
surgery
NCT03402945_exc_T7
Observation
previously enrolled in this trial
NCT03402945_exc_T8
Qualifier
Methicillin-resistant S. aureus (MRSA)
NCT03402945_exc_T9
Condition
colonized
NCT03402945_exc_T11
Drug
beta-lactam
NCT03402945_exc_T12
Drug
vancomycin
NCT03402945_exc_T13
Condition
allergy
NCT03402945_exc_T14
Scope
ta-lactam or vancomycin a fazolin or vancomycin, respectively, or to silver p
NCT03402945_exc_T15
Drug
cefazolin
NCT03402945_exc_T16
Drug
vancomycin
NCT03402945_exc_T17
Drug
silver